Antibody Neutralization of HIV-1 Crossing the Blood-Brain Barrier

Código QR

Antibody Neutralization of HIV-1 Crossing the Blood-Brain Barrier

ABSTRACT HIV-1 can cross the blood-brain barrier (BBB) to penetrate the brain and infect target cells, causing neurocognitive disorders as a result of neuroinflammation and brain damage. Here, we examined whether antibodies targeting the HIV-1 envelope glycoproteins interfere with the transcytosis o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Valérie Lorin, Anne Danckaert, Françoise Porrot, Olivier Schwartz, Philippe V. Afonso, Hugo Mouquet
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2020
Materias:	antibodies blood brain barrier HIV-1 neutralization transcytosis Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/9f247b0ebedf4ff9954a82cb5fc1720f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Multifunctional Nanopolymers for Blood–Brain Barrier Delivery and Inhibition of Glioblastoma Growth through EGFR/EGFRvIII, c-Myc, and PD-1
por: Rameshwar Patil, et al.
Publicado: (2021)

Encephalitic Alphaviruses Exploit Caveola-Mediated Transcytosis at the Blood-Brain Barrier for Central Nervous System Entry
por: Hamid Salimi, et al.
Publicado: (2020)

Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection
por: Zanele Ditse, et al.
Publicado: (2020)

Distinct Immunoglobulin Fc Glycosylation Patterns Are Associated with Disease Nonprogression and Broadly Neutralizing Antibody Responses in Children with HIV Infection
por: M. Muenchhoff, et al.
Publicado: (2020)

Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer
por: William D. Tolbert, et al.
Publicado: (2021)

Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects
por: Franck P. Dupuy, et al.
Publicado: (2019)

Wnt Signaling in Inner Blood–Retinal Barrier Maintenance
por: Felix Yemanyi, et al.
Publicado: (2021)

A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies
por: Meredith E. Davis-Gardner, et al.
Publicado: (2020)

Anti-Drug Antibodies in Pigtailed Macaques Receiving HIV Broadly Neutralising Antibody PGT121
por: Wen Shi Lee, et al.
Publicado: (2021)

Overcoming the Blood–Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours
por: Ferraris C, et al.
Publicado: (2020)

Role of the Antigen Capture Pathway in the Induction of a Neutralizing Antibody Response to Anthrax Protective Antigen
por: Anita Verma, et al.
Publicado: (2018)

Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants
por: David R. Martinez, et al.
Publicado: (2020)

Cross-Strain Neutralizing and Protective Monoclonal Antibodies against EEEV or WEEV
por: Amanda L. Phelps, et al.
Publicado: (2021)

Differences in the Binding Affinity of an HIV-1 V2 Apex-Specific Antibody for the SIV<sub>smm/mac</sub> Envelope Glycoprotein Uncouple Antibody-Dependent Cellular Cytotoxicity from Neutralization
por: Benjamin von Bredow, et al.
Publicado: (2019)

Development of TIMP1 magnetic nanoformulation for regulation of synaptic plasticity in HIV-1 infection
por: Atluri VSR, et al.
Publicado: (2016)

Norovirus Escape from Broadly Neutralizing Antibodies Is Limited to Allostery-Like Mechanisms
por: Abimbola O. Kolawole, et al.
Publicado: (2017)

AIDS Vaccine Research Subcommittee (AVRS) Consultation: Early-Life Immunization Strategies against HIV Acquisition
por: Anjali Singh, et al.
Publicado: (2019)

Chemoenzymatic Synthesis and Antibody Binding of HIV-1 V1/V2 Glycopeptide-Bacteriophage Q<i>β</i> Conjugates as a Vaccine Candidate
por: Guanghui Zong, et al.
Publicado: (2021)

Structural Basis for a Neutralizing Antibody Response Elicited by a Recombinant Hantaan Virus Gn Immunogen
por: Ilona Rissanen, et al.
Publicado: (2021)

Use of Quantitative Dried Blood Spots to Evaluate the Post-Vaccination Level of Neutralizing Antibodies against SARS-CoV-2
por: Alexandre Marchand, et al.
Publicado: (2021)

IMMUNOLOGICAL CHARACTERISTIC OF SYNTHETIC PEPTIDES SIMILAR TO ACTUAL HIV ANTIGEN DETERMINANTS
por: S. V. Korobova, et al.
Publicado: (2016)

Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies
por: Emily N. Gallichotte, et al.
Publicado: (2019)

Detection of rabies viral neutralizing antibodies in the Puerto Rican Brachyphylla cavernarum
por: Andrew Hirsbrunner, et al.
Publicado: (2020)

Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity
por: Melissa Ghulam-Smith, et al.
Publicado: (2017)

Optimizing superparamagnetic iron oxide nanoparticles as drug carriers using an in vitro blood–brain barrier model
por: Shi D, et al.
Publicado: (2016)

Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
por: Sagun Parakh, et al.
Publicado: (2021)

CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice
por: Biju Bhargavan, et al.
Publicado: (2021)

Editorial: Organization and Functional Properties of the Blood-Brain Barrier
por: Darryl R. Peterson, et al.
Publicado: (2021)

Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma
por: Qian-Ying Zhu, et al.
Publicado: (2020)

Pathoanatomical Pattern of Brain Damage of White Mice Infected with Experimental Anthrax
por: D. D. Briukhova, et al.
Publicado: (2020)

Matrix metalloproteinase-9 and p53 involved in chronic fluorosis induced blood-brain barrier damage and neurocyte changes
por: Shen Qing-Feng, et al.
Publicado: (2019)

Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment
por: Lin Tang, et al.
Publicado: (2021)

Neutralizing antibody response to SARS-CoV-2 persists 9 months post symptom onset in mild and asymptomatic patients
por: Olivier Bylicki, et al.
Publicado: (2021)

Fixations of the HIV-1 env gene refute neutralism: New evidence for pan-selective evolution
por: Valenzuela,Carlos Y, et al.
Publicado: (2010)

Neutralization Mechanisms of Two Highly Potent Antibodies against Human Enterovirus 71
por: Ling Zhu, et al.
Publicado: (2018)

CD4<sup>+</sup> T Cell-Mimicking Nanoparticles Broadly Neutralize HIV-1 and Suppress Viral Replication through Autophagy
por: Gang Zhang, et al.
Publicado: (2020)

Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope
por: Brandyn R. West, et al.
Publicado: (2018)

Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study
por: Frank-Peter Tillmann, et al.
Publicado: (2021)

Encapsulated n-Butylidenephthalide Efficiently Crosses the Blood–Brain Barrier and Suppresses Growth of Glioblastoma
por: Lin YL, et al.
Publicado: (2020)

Mouse Adenovirus Type 1 Early Region 1A Effects on the Blood-Brain Barrier
por: Nagaraja Tirumuru, et al.
Publicado: (2016)